x

Posted 08 March, 2023

Pediatrix Medical Group, Inc. appointed new CEO

CEO Change detected for ticker NYSE:MD in a 8-K filed on 08 March, 2023.


  On March 8, 2023, the Board of Directors (the "Board") of Pediatrix Medical Group, Inc., a Florida corporation (the "Company"), elected James D. Swift, M.D., the Company's Chief Executive Officer, to the Board to fill a vacancy created by the resignation of Roger J. Medel M.D., who resigned from the Board effective March 7, 2023.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Pediatrix Medical Group, Inc.
Health Care/Life Sciences • Healthcare Provision
Pediatrix Medical Group, Inc. engages in the provision of physician services. It includes newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care. The company was founded by Roger J. Medel in 1979 and is headquartered in Sunrise, FL.
Market Cap
$1.25B
View Company Details
Pediatrix Medical Group, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 8, 2023, the Board of Directors (the "Board") of Pediatrix Medical Group, Inc., a Florida corporation (the "Company"), elected James D. Swift, M.D., the Company's Chief Executive Officer, to the Board to fill a vacancy created by the resignation of Roger J. Medel M.D., who resigned from the Board effective March 7, 2023. Dr. Medel's resignation was not the result of any disagreement between the Company and Dr. Medel, known to an executive officer of the Company, on any matter relating to the Company's operations, policies, or practices.


Directors who are also employees of the Company, including Dr. Swift, receive no additional compensation for serving as directors. Dr. Swift is not a party to any arrangement or understanding with any person pursuant to which he was elected as a director, nor is he a party to any transaction required to be disclosed under Item 404(a) of Regulation S-K involving the Company that has not previously been disclosed.